Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + HRT in R/R DLBCL with High Tumor Burden
NCT06867536Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Complete Remission Rate. Started Apr 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06867536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867536.